Business
Nordson Corporation Reports Record Fourth Quarter and Fiscal Year 2025 Results
Fourth Quarter: Sales were $752 million, growth of 1% over prior year Earnings per diluted share were $2.69 Adjusted earnings per diluted share were $3.03,
About this update from Nordson Corporation
[{"type":"text","content":"\nFourth Quarter:\n\n\nSales were $752 million, growth of 1% over prior year\n\n\nEarnings per diluted share were $2.69\n\n\nAdjusted earnings per diluted share were $3.03, growth of 9% over prior year\n\n\nFull Year:\n\n\nRecord sales of $2.8 billion, growth of 4% over prior year’s record sales\n\n\nEarnings per diluted share were $8.51\n\n\nAdjusted earnings per diluted share were $10.24, growth of 5% over prior year\n\n\nFiscal 2026 Guidance:\n\n\nFiscal 2026 forecasted sales range between $2,830 to $2,950 million and adjusted earnings in the range of $10.80 to $11.50\n\n\n WESTLAKE, Ohio--(BUSINESS WIRE)--\nNordson Corporation (Nasdaq: NDSN) today reported results for the fiscal fourth quarter ended October 31, 2025. Sales were $752 million, a 1% increase compared to the prior year’s fourth quarter sales of $744 million. The increase in fourth quarter 2025 sales included favorable currency translation of 2% and a 1% acquisition impact, which was partially offset by the medical contract manufacturing divestiture and an organic sales decrease of 1%.\n\nNet income was $152 million, or earnings per diluted share of $2.69, compared to prior year’s fourth quarter net income of $122 million, or earnings per diluted share of $2.12. Adjusted net income was $171 million, up from prior year adjusted net income of $160 million. Fourth quarter 2025 adjusted earnings per diluted share were $3.03, a 9% increase compared to prior year adjusted earnings per diluted share of $2.78.\n\nEBITDA in the fourth quarter was $256 million, or 34% of sales, an increase of 6% compared to prior year EBITDA of $241 million, or 32% of sales.\n\nCommenting on the Company’s fiscal 2025 fourth quarter results, Nordson President and Chief Executive Officer Sundaram Nagarajan said, “We had a strong operational finish to fiscal 2025, and I want to thank our teams for delivering value to our customers and shareholders. Adjusted earnings per share increased 9% year-over-year, which was at the high end of our fourth quarter guidance. Sales increased 1%, inclusive of the divestiture of our medical contract manufacturing business that closed on September 2, 2025. Importantly, we achieved record EBITDA margin and free cash flow conversion of 128% resulting in continued balanced capital allocation of ongoing share repurchases, dividend payments and further debt reducti...